Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
After a summer slumber, the biotech IPO market is back in full swing with three new pricings dropping Wednesday and two SPACs entering the ring.
DiCE Therapeutics and Tyra Biosciences each hit Nasdaq on Wednesday with nine-figure raises, while small-cap Pasithea Therapeutics also debuted with a $24 million raise. The pricings have pushed the combined industry raise north of $13 billion so far in 2021, per the Endpoints News tracker, a figure likely to eclipse last year’s record total of $16.5 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.